home / stock / vstm / vstm news

VSTM News and Press, Verastem Inc. From 11/04/25

Stock Information
Company Name: Verastem Inc.
Stock Symbol: VSTM
Market: NASDAQ
Website: verastem.com
Menu
VSTM VSTM Quote VSTM Short VSTM News VSTM Articles VSTM Message Board
Get VSTM Alerts

News, Short Squeeze, Breakout and More Instantly...
VSTM - Verastem Oncology drops despite Q3 double beat

2025-11-04 12:12:01 ET More on Verastem Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript Verastem, Inc. 2025 Q3 - Results - Earnings Call Presentation Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade) Verastem signals ...
VSTM - Verastem signals confidence in AVMAPKI FAKZYNJA CO-PACK growth and prepares for pivotal 2026 clinical milestones

2025-11-04 10:17:10 ET More on Verastem Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript Verastem, Inc. 2025 Q3 - Results - Earnings Call Presentation Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade) Verastem Q3 2025 ...

VSTM - Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript

2025-11-04 10:16:25 ET Verastem, Inc. (VSTM) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Julissa Viana - Vice President of Corporate Communications & Investor Relations Daniel Paterson - President, CEO & Director Matthew Ros - Ch...

VSTM - Verastem Non-GAAP EPS of -$0.54 beats by $0.07, revenue of $11.2M beats by $5.44M

2025-11-04 07:34:22 ET More on Verastem Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade) Verastem, Inc. 2025 Q2 - Results - Earnings Call Presentation Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript Verastem Q3 2025 ...
VSTM - Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $11.2 million VS-7375 cleared first two monotherapy dose levels with no dose-limiting toxicities reported; no nausea, vomiting or diarrhea greater than Grade 1 were observed Enrollment initiated for VS-7375 i...

VSTM - Expected US Company Earnings on Tuesday, November 4th, 2025

Advanced Energy Industries Inc. (AEIS) is expected to report $1.16 for Q3 2025 Neuropace Inc. (NPCE) is expected to report $-0.2 for Q3 2025 Oportun Financial Corporation (OPRT) is expected to report $0.2 for Q3 2025 trivago N.V. (TRVG) is expected to report $0.07 for Q3 2025 Alle...

VSTM - Here are the major earnings before the open Tuesday

2025-11-03 18:00:53 ET Major earnings expected before the bell on Tuesday include: Pfizer ( PFE ) Shopify ( SHOP ) Uber Technologies ( UBER ) BP p.l.c. ( BP ) Spotify Technology S.A. ( SPOT ) Read the full article on Seeking Alpha For ...
VSTM - Verastem Q3 2025 Earnings Preview

2025-11-03 11:23:51 ET More on Verastem Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade) Verastem, Inc. 2025 Q2 - Results - Earnings Call Presentation Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript Verastem climbs o...

VSTM - Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reported Promising anti-tumor activity observed in patients with various solid tumors, including advanced pancreatic ductal adenocarcinoma No nausea, vomiting, or diarrhea greater...

VSTM - Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates o...
Previous 10 Next 10